Cargando…

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer

BACKGROUND: Olaparib is an oral inhibitor of polyadenosine 5’-diphosphoribose polymerization (PARP) that has previously shown signs of activity in patients with BRCA mutations and pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: In this phase 1 dose-escalation trial in patients with un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yarchoan, Mark, Myzak, Melinda C., Johnson, Burles A., De Jesus-Acosta, Ana, Le, Dung T., Jaffee, Elizabeth M., Azad, Nilofer S., Donehower, Ross C., Zheng, Lei, Oberstein, Paul E., Fine, Robert L., Laheru, Daniel A., Goggins, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546463/ https://www.ncbi.nlm.nih.gov/pubmed/28454122 http://dx.doi.org/10.18632/oncotarget.17237

Ejemplares similares

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers – a new active regimen
por: Slater, S, et al.
Publicado: (2002)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
por: Gupta, Amol, et al.
Publicado: (2023)

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
por: Yarchoan, Mark, et al.
Publicado: (2019)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008)

Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Alliot, C
Publicado: (2006)

Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study
por: Ogawa, Kohei, et al.
Publicado: (2012)

Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
por: Rudek, Michelle A., et al.
Publicado: (2016)

Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2006)

MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity
por: Yarchoan, Mark, et al.
Publicado: (2019)

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
por: Botrus, Gehan, et al.
Publicado: (2022)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer
por: Christenson, Eric S., et al.
Publicado: (2022)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial
por: Michel, P, et al.
Publicado: (2006)

A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
por: De Jesus-Acosta, Ana, et al.
Publicado: (2011)

A phase II irinotecan–cisplatin combination in advanced pancreatic cancer
por: Markham, C, et al.
Publicado: (2003)

MCC Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib
por: Jahan, Zeenat, et al.
Publicado: (2022)

Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
por: Sharma, Anup, et al.
Publicado: (2017)

Inhibiting the MCM8‐9 complex selectively sensitizes cancer cells to cisplatin and olaparib
por: Morii, Issay, et al.
Publicado: (2019)

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2022)

Correction: Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
por: Sharma, Anup, et al.
Publicado: (2020)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

Advanced Gastric Carcinoma Chemotherapy with Cisplatin, Mitomycin C, BCNU, and 5-Fluorouracil in Combination
por: Kim, Re Hwe, et al.
Publicado: (1987)

Mycobacterial helicase Lhr abets resistance to DNA crosslinking agents mitomycin C and cisplatin
por: Warren, Garrett M, et al.
Publicado: (2023)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
por: Moutafi, Myrto, et al.
Publicado: (2023)

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
por: Sekine, I, et al.
Publicado: (2008)

Correction: A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
por: Viúdez, Antonio, et al.
Publicado: (2017)

Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer
por: Lordick, F, et al.
Publicado: (2003)

Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
por: Sugiyama, T, et al.
Publicado: (1999)

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
por: Masuda, N., et al.
Publicado: (1993)

A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer.
por: Hickish, T. F., et al.
Publicado: (1998)

Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer
por: Urruticoechea, A, et al.
Publicado: (2005)

A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
por: Viúdez, Antonio, et al.
Publicado: (2016)

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.
por: Ellis, P. A., et al.
Publicado: (1995)

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
por: Gorodnova, Tatiana V., et al.
Publicado: (2021)

Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer
por: Xie, Kejie, et al.
Publicado: (2021)

Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells
por: Gao, Jianwen, et al.
Publicado: (2021)

Editorial Comment on “Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin”
por: Hatano, Koji
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bdls6arn4elc3q31tncm8dh687